270 related articles for article (PubMed ID: 6113833)
1. Pharmacological studies on timiperone, a new neuroleptic drug. Part I: Behavior effects.
Yamasaki T; Kojima H; Sakurai T; Kasahara A; Watanabe S; Fujiwara M; Ueki S
Arzneimittelforschung; 1981; 31(4):701-7. PubMed ID: 6113833
[No Abstract] [Full Text] [Related]
2. Pharmacological study of [2-chloro-11-(2-dimethylaminoethoxy) dibenzo[b,f]thiepine] (zotepine), a new neuroleptic drug.
Uchida S; Honda F; Otsuka M; Satoh Y; Mori J; Ono T; Hitomi M
Arzneimittelforschung; 1979; 29(10):1588-94. PubMed ID: 42413
[TBL] [Abstract][Full Text] [Related]
3. Behavioral pharmacologic studies in the monkey with DD-3480.
Shibuya T; Nishimori T; Matsuda H; Chen PC
Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):251-4. PubMed ID: 6125481
[TBL] [Abstract][Full Text] [Related]
4. Bromoperidol, a new potent neuroleptic of the butyrophenone series. Comparative pharmacology of bromoperidol and haloperidol.
Niemegeers CJ; Janssen PA
Arzneimittelforschung; 1974 Jan; 24(1):45-52. PubMed ID: 4406109
[No Abstract] [Full Text] [Related]
5. Neuropharmacological profile of MD 790501, a new benzamide derivative.
Jalfre M; Bucher B; Dorme N; Mocquet G; Porsolt RD
Arch Int Pharmacodyn Ther; 1983 Aug; 264(2):232-56. PubMed ID: 6139097
[TBL] [Abstract][Full Text] [Related]
6. A critical assessment of behavioural test procedures used to analyse dopaminergic and antidopaminergic drugs.
Nohria V
Methods Find Exp Clin Pharmacol; 1983; 5(6):357-64. PubMed ID: 6137599
[No Abstract] [Full Text] [Related]
7. Pharmacological and biochemical studies on a new potential neuroleptic, N-(1-benzyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-08050).
Usuda S; Sano K; Maeno H
Arch Int Pharmacodyn Ther; 1979 Sep; 241(1):68-78. PubMed ID: 43118
[TBL] [Abstract][Full Text] [Related]
8. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
Christensen AV; Arnt J; Hyttel J; Svendsen O
Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
[TBL] [Abstract][Full Text] [Related]
9. Experimental evaluation of the possible neuroleptic activity of clomipramine.
Balsara JJ; Chandorkar AG
Indian J Physiol Pharmacol; 1978; 22(3):263-9. PubMed ID: 31334
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological studies on timiperone, a new neuroleptic drug Part II: General pharmacological properties.
Yamasaki T; Kojima H; Tanaka M; Aibara S; Hirohashi M; Kasai Y; Tsubokawa M; Watanabe K; Akashi A
Arzneimittelforschung; 1981; 31(4):707-15. PubMed ID: 6113834
[TBL] [Abstract][Full Text] [Related]
11. Behavioral pharmacology of the benzamides as compared to standard neuroleptics.
Worms P
Adv Biochem Psychopharmacol; 1982; 35():7-16. PubMed ID: 6128876
[No Abstract] [Full Text] [Related]
12. Synthesis and pharmacological investigations of new 6-oxo-1,2,3,4-tetrahydro-6H-pyrimido[2,1-b]quinazoline derivatives.
Korzycka L; Szadowska A; Pakulska W
Pharmazie; 1994 Nov; 49(11):815-9. PubMed ID: 7838867
[TBL] [Abstract][Full Text] [Related]
13. Effects of yohimbine on dopamine dependent behaviours in rats and mice.
Bende MM; Bapat TR; Balsara JJ; Chandorkar AG
Indian J Physiol Pharmacol; 1990 Jul; 34(3):195-200. PubMed ID: 2286423
[TBL] [Abstract][Full Text] [Related]
14. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological properties of new antipsychotic agents: use of animal models.
Puech AJ; Rioux P; Poncelet M; Brochet D; Chermat R; Simon P
Neuropharmacology; 1981 Dec; 20(12B):1279-84. PubMed ID: 6119637
[No Abstract] [Full Text] [Related]
16. Pharmacological evaluation of clomacran, a new potent psychotropic agent.
Fowler PJ; Zirkle CL; Macko E; Kaiser C; Sarau H; Tedeschi DH
Arzneimittelforschung; 1977; 27(4):866-72. PubMed ID: 17419
[No Abstract] [Full Text] [Related]
17. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
Bartoszyk GD; Harting J; Minck KO
J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of apomorphine induced climbing: is it a valid model for neuroleptic activity?
Wallach MB; Hedley LR; Peterson KE; Schulz CH
Proc West Pharmacol Soc; 1980; 23():93-8. PubMed ID: 6105667
[No Abstract] [Full Text] [Related]
19. Is dopamine antagonism a requisite of neuroleptic activity?
Greenblatt EN; Coupet J; Rauh E; Szucs-Myers VA
Arch Int Pharmacodyn Ther; 1980 Nov; 248(1):105-19. PubMed ID: 6111298
[TBL] [Abstract][Full Text] [Related]
20. omega-Amino-2-hydroxy-p-fluorobutyrophenones: synthesis and preliminary pharmacological evaluation.
Cascio G; Erba R; Manghisi E; Biazzi A; Ferni G; Fregnan GB
Farmaco Sci; 1980 Jul; 35(7):605-14. PubMed ID: 6108874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
